Congestive heart failure and toxic digoxin levels: role of cholestyramine.
We report 2 patients with congestive heart failure and concomitant toxic serum digoxin levels in whom cholestyramine administration increased clearance of digoxin and decreased serum digoxin elimination half-lives. Cholestyramine's gastrointestinal binding of enterohepatically-recycled and enterally-secreted digoxin enhanced elimination, allowing a more rapid return to therapeutic drug levels.
Roberge
R J
RJ
Department of Emergency Medicine of the Western Pennsylvania Hospital, Pittsburgh 15224, USA.
Sorensen
T
T
D000368:Aged; D000369:Aged, 80 and over; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects* / Q000097:blood; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001774:Blood Chemical Analysis; D002792:Cholestyramine Resin / Q000627:therapeutic use*; D004077:Digoxin / Q000009:adverse effects* / Q000097:blood; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006207:Half-Life; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D013902:Radiography, Thoracic
D000889:Anti-Arrhythmia Agents; D000924:Anticholesteremic Agents; D004232:Diuretics; D002792:Cholestyramine Resin; D004077:Digoxin; D005665:Furosemide